Daniel S. Lorrain - 25 Nov 2024 Form 4 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Signature
/s/ Peter Slover, Attorney-in-Fact
Issuer symbol
CTNM
Transactions as of
25 Nov 2024
Net transactions value
-$16,177
Form type
4
Filing time
27 Nov 2024, 17:06:15 UTC
Previous filing
20 Nov 2024
Next filing
31 Jan 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTNM Class A Common Stock Sale $16,177 -1,010 -0.6% $16.02 168,562 25 Nov 2024 Direct F1, F2
holding CTNM Class A Common Stock 3,898 25 Nov 2024 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 19, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.14, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.